Navigation Links
A Study Finds VENs Devastated in FTD

The official journal of the American Neurological Association, examined brain tissue acquired at autopsy and found that VENs were devastated in FTD//.

Von Economo neurons (VENs) are uniquely shaped brain cells that seem to have evolved in a select group of socially complex species: great apes, humans, and, as reported last month, whales. Across species, VENs are localized to frontal brain regions associated with cognition, emotion and social behavior. Frontotemporal dementia (FTD), a common neurodegenerative condition, is characterized by early breakdown in social and emotional awareness and is accompanied by atrophy and dysfunction in the brain areas where VENs are located. A new study published in the December 2006 issue of Annals of Neurology.

Led by William W. Seeley, M.D., of the Department of Neurology at the University of California, San Francisco, researchers quantified anterior cingulate cortex VENs in seven patients with FTD, five with Alzheimer’s disease (AD), and seven control subjects who were not demented. All FTD patients had prominent changes in social behavior and emotion, sometimes accompanied by deficits in cognitive function.

In contrast, AD patients had an array of cognitive symptoms, including memory and language impairment, with little change in social behavior. The researchers found early, severe, and selective loss of VENs in FTD, which showed a 69% reduction compared to AD and controls after controlling for overall neuronal loss.

"Our findings suggest that selective VEN loss is a defining feature of FTD but does not apply to AD," the researchers state, adding that future research should explore how VEN loss relates to specific social/behavioral deficits in FTD and other disorders where such deficits are a defining feature.

VENs receive chemical signals from dopamine, serotonin, and vasopressin systems that play important roles in social and emotional bonding. These functions are disrupt ed early in FTD but spared in AD, the authors note. While drugs aimed at preserving VEN function may help curtail FTD symptoms, basic studies of VEN biophysical and molecular properties are needed to clarify the mechanisms that cause VENs to degenerate in FTD.

"Distinctive functions of these unique cells may prove invaluable in health, yet may also expose us to specific forms of developmental or later-life illness," the authors conclude. "The link forged here between VENs and FTD should spawn further studies of how human brain evolution relates to human brain disease."


Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: